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Introduction {#j_raon-2015-0047_s_001}
============

Gastric cancer is one of the major contributors to cancer-related deaths worldwide with estimated 989 600 new cases and 738 000 deaths in 2008.[@j_raon-2015-0047_ref_01],[@j_raon-2015-0047_ref_02] It is believed that complex interplay of genetic and environmental factors triggers the accumulation of numerous genetic and epigenetic alterations in cells, resulting in deregulation of normal cell functions and disruption of stomach linen homeostasis.[@j_raon-2015-0047_ref_03]-[@j_raon-2015-0047_ref_06] Individual genetic factors probably contribute to aberrant processes in the genesis of malignant phenotype. Among them, single nucleotide polymorphisms (SNPs) and other genetic variants play an important role as the main genetic elements in the aetiology of several complex diseases, including gastric cancer.[@j_raon-2015-0047_ref_07]-[@j_raon-2015-0047_ref_11] In gastric carcinogenesis this is further supported by the fact that only a small proportion of individuals exposed to the known environmental risk factors develop adenocarcinoma.[@j_raon-2015-0047_ref_05],[@j_raon-2015-0047_ref_10] Therefore, there is continuing interest for determining simple genetic tests for identifying individuals at high risk for the development of gastric tumours and for identifying patients with high risk for recurrence in order to ensure improved and early diagnosis as well as better survival of patients.

A majority of gastric cancer patients show chromosomal instability (CIN) resulting in aneuploidy.[@j_raon-2015-0047_ref_04],[@j_raon-2015-0047_ref_12],[@j_raon-2015-0047_ref_13] It has been suggested that tumour cells acquire aberrant chromosome numbers and other chromosomal defects as a result of deregulation of mechanisms responsible for maintaining the chromosomal number stability, such as spindle assembly checkpoint and chromosome segregation.[@j_raon-2015-0047_ref_14],[@j_raon-2015-0047_ref_15]However, mutations in mitotic genes are rare, due to the fact that severe defects of these genes would trigger cell death by cell-surveillance early in the development.[@j_raon-2015-0047_ref_14]-[@j_raon-2015-0047_ref_17] Studies revealed that subtle changes in mitotic segregation genes, controlling chromatids separation or regulating the progress of mitosis, could be prime candidates for inducing the slow process of accumulation of genetic changes, leading to CIN.[@j_raon-2015-0047_ref_15],[@j_raon-2015-0047_ref_18]-[@j_raon-2015-0047_ref_20] The novel hypothesis is further supported by the fact that this process is slow, and explains the late onset of sporadic epithelial cancers[@j_raon-2015-0047_ref_21],[@j_raon-2015-0047_ref_22], as well as heterogeneous mutation load observed in different sections of tumours from individual patients.

The multidomain protein kinase BUB1B (BUB1-related kinase, known as MAD3 in yeast) plays a central role in the process of spindle assembly checkpoint (SAC), which prevents defects in the segregation of sister chromatids by delaying their separation until all chromatids have achieved correct attachments to the mitotic spindle.[@j_raon-2015-0047_ref_23],[@j_raon-2015-0047_ref_24] BUB1B is part of the mitotic checkpoint complex (MCC), which together with BUB3, MAD2 and CDC20 inhibits the anaphase-promoting complex/cyclosome (APC/C), delaying the onset of anaphase and ensuring proper chromosome segregation.[@j_raon-2015-0047_ref_25] The protein BUB1B has also been localized to the kinetochores and is important for stabilizing the kinetochore-microtubule interactions and chromosome alignment.[@j_raon-2015-0047_ref_26] A dual specificity protein kinase TTK (alias MPS1) is crucial for the spindle assembly checkpoint, for chromosome biorientation on the mitotic spindle and for ensuring accurate chromosome segregation.[@j_raon-2015-0047_ref_27],[@j_raon-2015-0047_ref_28] Inhibitor and chemical genetics studies showed that TTK activity facilitates the conformational activation of MAD2 from open to closed form (C-MAD2) capable of CDC20 binding and inhibition, thus delaying the onset of anaphase.[@j_raon-2015-0047_ref_29] TTK is probably implicated in the recruitment of the MAD1-C-MAD2 complex to kinetochores and during mitosis its activity is continuously required to recruit O-Mad2 to the Mad1-C-Mad2 core.[@j_raon-2015-0047_ref_30] Furthermore, TTK is required for CENP-E recruitment, whose activity is essential for metaphase chromosome alignment.[@j_raon-2015-0047_ref_30]

In the present study we examined polymorphisms rs151658 (C\>G) in *TTK* gene, rs1031963 (C\>T) and rs1801376 (A\>G) in *BUB1B* gene in the population of Slovenian patients with an advanced gastric cancer and their impact on gastric cancer risk. We also examined the associations of these genetic variants with clinico-histopathological features of patients.

Patients and methods {#j_raon-2015-0047_s_002}
====================

Research subjects {#j_raon-2015-0047_s_003}
-----------------

The study population (n = 284) consisted of 108 Slovenian patients with gastric cancer and 176 control subjects who at the time of peripheral blood extraction did not have cancer. Tumour and corresponding non-tumour tissues at least 7 cm away from the edge of the adenocarcinoma were collected from patients who were admitted to the Clinical Department for Abdominal Surgery at the University Medical Centre Ljubljana and Department for Pathology at the Institute of Oncology Ljubljana during the years 2000-2008. Samples were macrodissected by pathologist, frozen in liquid nitrogen and stored at −70°C. Comprehensive medical data were obtained from registries and pathologist's evaluation. The following clinico-histopathological parameters were recorded: tumour differentiation (grade), location, blood and lymphatic vessel invasion (vascular invasion, perineural invasion), occurrence of tumour cells in the lymphatic vessels (lymphatic invasion), depth of invasion (pT), lymph node involvement (pN), and presence of distant metastases (pM). The gastric cancer cases were classified into diffuse type (n = 46) and intestinal (n = 58) according to Lauren classification. The mean age ± standard deviation (SD) of patients was 66.12 ± 12.02 (range, 33-87 years), and the percentage of men was 63.0%. Cases lost to follow-up (n = 6) and those, who died within 30 days after surgery (n = 2), were excluded from survival analyses. The control population was randomly selected during the years 1999-2007 and shared the ethnic and geographic background of the gastric cancer patients. The research was approved by the National Medical Ethics Committee of the Republic of Slovenia and confidentiality of personal medical data as well as other data relating to individual identification has been assured in accordance with the Helsinki Declaration.

Genotyping {#j_raon-2015-0047_s_004}
----------

Genomic DNA from gastric tumour and nontumour tissues was extracted using a Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA) and QuickGene™ DNA Tissue Kit S (Fujifilm Corporation, Tokyo, Japan) on QuickGene-810 DNA isolation system (Fujifilm) according to manufacturer's protocol. Genomic DNA from control population was extracted from peripheral blood samples using Wizard® Genomic DNA Purification Kit (Promega) following the manufacturer's protocol. The DNA was quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific Inc.). Genotyping for polymorphism rs151658 (C\>G) in *TTK* gene, and polymorphisms rs1031963 (C\>T) and rs1801376 (A\>G) in *BUB1B* gene was performed using TaqMan-based allele-specific polymerase chain reaction assays on the ABI Prism 7000 Sequencing Detection System apparatus (Applied Biosystems, Foster City, CA, USA) according to the procedure recommended by Applied Biosystems. The 10 μL reaction volume contained 100 ng of DNA. Assay IDs were: C_3181603_10, C_1237153_10, and C_3052718_1. In order to confirm the veracity of the results, the polymorphisms were re-genotyped by direct sequencing on a randomly selected smaller batch of samples.

Immunoblot analysis {#j_raon-2015-0047_s_005}
-------------------

A total of 21 paired gastric adenocarcinoma (GA) and adjacent control tissue samples were ground with a mortar and pestle in liquid nitrogen and lysed with 7 mol/L urea, 2 mol/L thiourea, 40 g/L CHAPS, with a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). For every 10 mg tissue, 50 μl lysis buffer was added. After sonication on ice (3 × 10 s), the samples were incubated for 1 h on ice with occasional vortexing, and then centrifuged at 20,000 × g for 1 h at 4°C. The supernatants were collected and the protein concentrations were determined using the commercial Bradford reagent (Thermo Fisher Scientific, Waltham, MA, USA) with BSA used as the standard. Immunoblot analysis was performed on 42 samples. A total of 30 μg protein per sample was loaded onto 10% gels, separated using SDS-PAGE, and transferred onto PDVF membranes (Millipore, Billerica, MA, USA), which were then blocked in 50 g/L skimmed milk 1 h. The primary antibody was used in the following dilution: anti-Mpsl (anti-TTK) antibody, 1 pg/ml (ab11108, Abcam, Cambridge, UK). Horseradish peroxidase-conjugated secondary antibody was used in the following dilution: goat anti-mouse antibody, 1:5000 (115-035-062, Jackson ImmunoResearch, Newmarket, Suffolk, UK). The proteins were revealed by chemiluminescence using LAS-4000 CCD camera (Fujifilm, Tokyo, Japan). The blots were then quantified with Multi Gauge software (Fujifilm) and the intensities were normalized to Ponceau-S-stained membranes, to allow for loading and transfer variations.

Statistical and bioinformatic analyses {#j_raon-2015-0047_s_006}
--------------------------------------

Statistical evaluation of the genotyping data was carried out using the χ^2^ or Fischer's exact tests to compare the groups regarding genotype frequencies. Hardy-Weinberg (HW) equilibrium was calculated with an online program (<http://www.genes.org.uk/software/hardy-weinberg.shtml>).[@j_raon-2015-0047_ref_31] Survival was assessed by the Kaplan-Meier method and differences between groups were evaluated using the log-rank test. Multivariate survival analyses were further performed using the Cox proportional-hazards regression model. In the Cox multivariate analyses, forced entry procedure was used to determine the predictor variables. Only the variables that resulted in p-values \< 0.05 in the Kaplan-Meier test were entered into the Cox proportional hazard model for the determination of independent prognostic factors for gastric cancer. The postoperative period was measured from the date of surgery to the date of the last follow-up or death. Statistical software used for calculations was IBM® SPSS® Statistics Version 20. For all statistical tests, a probability level (p-value) of less than 0.05 was considered significant.

To assess the statistical significance of altered protein abundance in the immunoblotting (as the tumour vs. non-tumour paired samples), non-parametric Wilcoxon signed-rank test was used. The tests were double-sided and the values with p \< 0.05 with a confidence level of 95% were considered to be statistically significant. To assess the correlation of the altered protein abundance from the immunoblotting with the histopathological parameters, repeated measures ANOVA was used. The values with p \< 0.05 were considered to be statistically significant. Bonferroni post-tests were used to determine where the differences were significant. All of the analyses were performed using Microsoft Office Excel 2007 (Microsoft Corporation, Washington, USA) and GraphPad Prism 5 (GraphPad Software, Inc., California, USA).

In order to functionally evaluate intronic polymorphisms we identified their effect in the context of polymorphic biological sequences on protein binding motifs. We used web-based software PROMO, which is part of the ALGGENE web-server.[@j_raon-2015-0047_ref_32],[@j_raon-2015-0047_ref_33] The search for putative binding sites was performed using the following parameters: human species, all motifs, and all factors. The data for comparisons of genotype frequencies in European populations of examined SNPs in this study was extracted from the 1000 Genomes Project data platform using a specific version of the Ensembl browser (<http://browser.1000genomes.org>).[@j_raon-2015-0047_ref_34]

Results {#j_raon-2015-0047_s_007}
=======

Patients' survival is associated with certain clinico-pathological features {#j_raon-2015-0047_s_008}
---------------------------------------------------------------------------

The clinical information and demographic characteristics of selected patients with gastric cancer in this study are summarized in [Table 1](#j_raon-2015-0047_tab_001){ref-type="table"}. At the end of a period of up to 11 years of follow-up, a total of 69 patients out of 100 have died.

###### 

Clinicopathological characteristics of patients with gastric cancer

  Parameter                                     Number of patients (%)
  --------------------------------------------- ------------------------
  Age (years ± standard deviation) (n = 108)    66.12 ± 12.02
  Gender (n = 105)                              
    Male                                        68 (63.0)
    Age (years ± standard deviation) (n = 66)   65.07 ± 12.03
    Female                                      40 (37.0)
    Age (years ± standard deviation) (n = 39)   67.90 ± 11.94
  Lauren's classification (n = 104)             
    Intestinal                                  58 (55.8)
    Diffuse                                     46 (44.2)
  Location (n = 101)                            
    Upper                                       40 (39.6)
    Lower                                       34 (33.7)
    Mixed                                       27 (26.7)
  Grade/differentiation (n = 105)               
    Well                                        9 (8.6)
    Moderate                                    24 (22.9)
    Poor                                        72 (68.6)
  Vascular invasion (n = 80)                    
    Present                                     27 (33.8)
    Not present                                 53 (66.3)
  Perineural invasion (n = 95)                  
    Present                                     44 (46.3)
    Not present                                 51 (53.7)
  Lymphatic invasion (60)                       
    Present                                     53 (88.3)
    Not present                                 7 (11.7)
  pN (n = 105)                                  
    0                                           24 (22.9)
    1-2                                         15 (14.3)
    3-6                                         20 (19.0)
    \> 7                                        46 (43.8)
  pT (n = 105)                                  
    Muscularis propria                          6 (3.7)
    Subserosa                                   50 (42.6)
    Serosa                                      49 (36.1)

pN = number of positive regional lymph nodes; pT = tumour invasion

The overall 5-year survival was 33.5%. No statistically significant association between tested genetic variations and survival was observed (p \> 0.05). Univariate survival analysis showed that only Lauren's classification and lymph node involvement (pN) were significant prognostic factors. Diffuse type predicted shorter 5-year survival (logrank test, χ^2^ = 5.516, p = 0.019) with overall mean estimate of survival for patients with intestinal type 64.67 months ± 7.74 (SE) (CI = 49.50-79.84) and 39.73 months ± 6.83 (SE) (CI = 26.75-53.11) for patients with diffuse type of gastric cancer. Regarding the parameter pN, patients with 7 or more positive lymph nodes had shorter survival time of 21.93 months ± 4.30 (SE) with CI = 13.5030-36 (log-rank test, χ^2^ = 34.169, p = 0.000). Multivariate analysis was performed for the same set of patients with complete clinical data sets. Cox regression model included both significant variables, pN and tumour classification. The enter method showed significant improvement (p \< 0.05) if both parameters were entered into the model ([Table 2](#j_raon-2015-0047_tab_002){ref-type="table"}).

###### 

Multivariate survival analysis of clinic-pathological variables in gastric cancer patients

  Variable                  B[\*](#j_raon-2015-0047_tbl2_001){ref-type="table-fn"}   SE (B)   OR (95% CI)           P
  ------------------------- -------------------------------------------------------- -------- --------------------- -------
  pN                        0.670                                                    0.127    1.954 (1.525-2.504)   0.000
  Lauren's classification   0.591                                                    0.246    1.807 (1.116-2.925)   0.016

Predicted change in the hazard for a unit increase in the predictor.

CI = confidence interval; OR = odds ratio; pN = number of positive regional lymph nodes; SE = standard error

SNPs in *TTK* and *BUB1B* are associated with type, grade, and location of gastric cancer {#j_raon-2015-0047_s_009}
-----------------------------------------------------------------------------------------

Associations between clinicopathological parameters and genotypes of SNPs are presented in [Table 3](#j_raon-2015-0047_tab_003){ref-type="table"}. Statistical analysis revealed a weakly significant association for rs151658 genotypes C/G and risk of developing diffuse type of gastric cancer, and genotype G/G and risk of developing intestinal type of cancer (p = 0.049). Similar results were obtained for both male and female populations of patients (p = 0.047 and p = 0.024, respectively). Genotype A/A of rs1801376 polymorphism was significantly associated with higher risk of developing the diffuse type of gastric cancer in total and female populations of patients (p = 0.007). Interestingly, A/G genotype was under-represented in populations with diffuse type of gastric cancer. Genotype A/A of this polymorphism was also associated with the invasion of tumour cells into subserosa layer of stomach in male population (p = 0.009). A/A genotype was also associated with tumour location, namely, A/A frequencies were increased in patients with tumours disseminated across the whole stomach (p = 0.035).

###### 

Comparison of clinic-pathological features and genotypes *TTK* rs151658, *BUB1B* rs1031963, and *BUB1B* rs1801376 in patients with gastric cancer

  Parameter                                     Subject   Variant/Genotype        P                 
  ------------------------- ------------------- --------- ----------------------- ------------ ---- ----------------------
                                                          ***TTK* rs151658**                        
                                                          GG                      CG           CC   
  Lauren's classification   Intestinal          Total     17                      21           20   **0.049** χ^2^=6.033
  Diffuse                   5                   25        16                                        
                            Intestinal          Male      9                       10           14   **0.047** χ^2^=6.113
  Diffuse                   5                   20        8                                         
                            Intestinal          Female    8                       11           6    **0.024** F=7.499
  Diffuse                   0                   5         8                                         
                                                          ***BUB1B* rs1801376**                     
                                                          AA                      AG           GG   
                            Intestinal          Total     18                      33           7    **0.007**
  Diffuse                   28                  13        5                       χ^2^=9.951        
                            Intestinal          Male      15                      14           4    0.472 F=1.836
  Diffuse                   20                  9         4                                         
                            Intestinal          Female    3                       19           3    **0.007** F=9.688
  Diffuse                   8                   4         1                                         
                                                          ***BUB1B* rs1031963**                     
                                                          CC                      CT           TT   
  Tumour differentiation    Well                Total     1                       4            4    
                            Moderate                      7                       9            7    **0.035** F=9.642
                            Poor                          23                      39           7    
                            Well                Male      0                       2            3    
                            Moderate                      6                       7            2    0.139 F=6.439
                            Poor                          19                      20           6    
                            Well                Female    1                       2            1    
                            Moderate                      1                       2            5    **0.004** F=12.549
                            Poor                          19                      20           6    
                                                          ***BUB1B* rs1801376**                     
                                                          AA                      AG           GG   
  pT                        Muscularispropria   Total     1                       4            1    0.232 F=5.250
                            Subserosa                     27                      18           5    
                            Serosa                        18                      25           6    
                            Muscularispropria   Male      0                       3            1    **0.009** F=11.832
                            Subserosa                     22                      6            2    
                            Serosa                        13                      14           5    
                            Muscularispropria   Female    1                       1            0    0.816 F=1.967
                            Subserosa                     5                       12           3    
                            Serosa                        5                       11           1    
                                                          ***BUB1B* rs1801376**                     
                                                          AA                      AG           GG   
  Tumour                    Upper               Total     14                      23           3    
  location                  Lower                         13                      15           6    **0.035** F=10.104
                            Whole                         18                      6            3    

pT = tumour invasion

Genotype T/T of rs1031963 was associated with well differentiated tumours in total population (p = 0.035); however, when we stratified it into female and male populations, we observed a significant association of this genotype with moderately differentiated tumours in the female population (p = 0.004). Clinico-pathological features lymph node involvement (pN), depth of invasion (pT), vascular invasion, perineural invasion and lymphatic invasion did not show significant associations with investigated polymorphisms.

SNPs in BUB1B are associated with gastric cancer risk {#j_raon-2015-0047_s_010}
-----------------------------------------------------

The analyses of genotype frequencies in selected SNPs between cases and controls are shown in [Tables 4](#j_raon-2015-0047_tab_004){ref-type="table"} and [5](#j_raon-2015-0047_tab_005){ref-type="table"}. The frequencies of all genotypes in cases and control groups were in Hardy-Weinberg equilibrium.

###### 

Distribution of genotype frequencies of ***TTK*** rs151658, ***BUB1B*** rs1031963, and ***BUB1B*** rs1801376 between gastric cancer patients and control subjects

  Variants              Genotype   Cases (n)   Controls (n)   [p]{.smallcaps}     HWE (cases)        HWE (controls)
  --------------------- ---------- ----------- -------------- ------------------- ------------------ ------------------
  *TTK* rs151658        GG         24          55             χ^2^=3,628 0.163    χ^2^=1.08 0.299    χ^2^=2.87 0.090
  CG                    48         76                                                                
  C/C                   36         44                                                                
  *BUB1B* rs1031963     CC         32          48             χ^2^=1.059 0.589    χ^2^=0.345 0.557   χ^2^=0.035 0.852
  CT                    54         89                                                                
  TT                    18         39                                                                
  *BUB1B* rs1801376     AA         47          89             χ^2^=2.291 0.318    χ^2^=0.021 0.885   χ^2^=0.005 0.941
  AG                    49         69                                                                
  GG                    12         13                                                                
  *Male population*     AA         36          49             χ^2^=1.186 0.553    χ^2^=1.530 0.216   χ^2^=0.040 0.841
  AG                    24         39                                                                
  GG                    8          7                                                                 
  *Female population*   AA         11          40             F=6.955 **0.029**   χ^2^=3.352 0.067   χ^2^=0.013 0.909
  AG                    25         30                                                                
  GG                    4          6                                                                 

F = Fisher statistics; HWE = Hardy-Weinberg Equilibrium; [x]{.smallcaps}^2^ = chi-square statistics;

###### 

Odds ratios for *TTK* rs151658, *BUB1B* rs1031963, and *BUB1B* rs1801376 between the cases and controls and their effect on gastric cancer risk

  Genotype model          Cases (n)/Control group (n)   OR (95% CI)[\*](#j_raon-2015-0047_tbl5_001){ref-type="table-fn"}   P            P~Y~
  ----------------------- ----------------------------- ------------------------------------------------------------------ ------------ -------------
  ***BUB1B* rs1031963**                                                                                                                 
  Dominant                72/120                        0.900                                                              χ^2^=0.149   χ^2^=0.062
  TT+CT vs. CC            vs. 32/48                     (0.527-1.536)                                                      0.699        0.803
  Recessive               18/36                         0.797                                                              χ^2^=0.507   χ^2^=0.309
  TT vs. CT+CC            vs. 86/137                    (0.426-1.491)                                                      0.476        0.578
  Heterozygous            54/89                         0.910                                                              χ^2^=0.108   χ^2^=0.035
  CT vs. CC               vs. 32/48                     (0.520-1.594)                                                      0.742        0.853
  *Male population*                                                                                                                     
  Dominant                41/101                        0.364                                                              χ^2^=9.848   χ^2^=8.834
  TT+CT vs. CC            vs. 26/26                     (0.192-0.691)                                                      **0.002**    **0.003**
  Recessive               11/26                         0.763                                                              χ^2^=0.467   χ^2^=0.241
  TT vs. CT+CC            vs. 56/101                    (0.351-1.659)                                                      0.494        0.623
  Heterozygous            30/75                         0.400                                                              χ^2^=6.959   χ^2^=6.057
  CT vs. CC               vs. 26/26                     (0.201-0.797)                                                      **0.008**    **0.014**
  *Female population*                                                                                                                   
  Dominant                31/57                         1.994                                                              χ^2^=1.862   χ^2^=1.281
  TT+CT vs. CC            vs. 6/22                      (0.731-5.437)                                                      0.172        0.258
  Recessive               7/13                          1.185                                                              χ^2^=0.107   χ^2^=0.004
  TT vs. CT+CC            vs. 30/66                     (0.429-3.269)                                                      0.743        0.949
  Heterozygous            24/44                         2.000                                                              χ^2^=1.775   χ^2^=1.188
  CT vs. CC               vs. 6/22                      (0.714-5.606)                                                      0.183        0.276
  ***BUB1B* rs1801376**                                                                                                                 
  Dominant                61/82                         1.409                                                              χ^2^=1.927   χ^2^=1.601
  GG+AG vs. AA            vs. 47/89                     (0.868-2.287)                                                      0.165        0.206
  Recessive               12/13                         1.519                                                              χ^2^=0.999   χ^2^=0.615
  GG vs. AA+AG            vs. 96/158                    (0.666-3.465)                                                      0.318        0.433
  Heterozygous            49/69                         1.345                                                              χ^2^=1.304   χ^2^=1.025
  AG vs. AA               vs. 47/89                     (0.808-2.237)                                                      0.253        0.311
  *Malepopulation*                                                                                                                      
  Dominant                32/46                         0.947                                                              χ^2^=0.029   χ^2^=0.0002
  GG+AG vs. AA            vs. 36/49                     (0.508-1.766)                                                      0.864        0.990
  Recessive               8/7                           1.676                                                              χ^2^=0.917   χ^2^=0.466
  GG vs. AA+AG            vs. 60/88                     (0.577-4.868)                                                      0.338        0.495
  Heterozygous            24/39                         0.838                                                              χ^2^=0.272   χ^2^=0.124
  AG vs. AA               vs. 36/49                     (0.430-1.630)                                                      0.602        0.725
  *Femalepopulation*                                                                                                                    
  Dominant                29/36                         2.929                                                              χ^2^=6.719   χ^2^=5.737
  GG+AG vs. AA            vs. 11/40                     (1.281-6.700)                                                      **0.010**    **0.017**
  Recessive               4/6                           1.296                                                              χ^2^=0.147   χ^2^=0.001
  GG vs. AA+AG            vs. 36/70                     (0.344-4.889)                                                      0.701        0.971
  Heterozygous            25/30                         3.030                                                              χ^2^=6.732   χ^2^=5.709
  AG vs. AA               vs. 11/40                     (1.292-7.108)                                                      **0.009**    **0.017**

p value with Yates correction

χ^2^ = chi-square statistics; OR = odds ratio; CI = confidence interval

The tested polymorphisms did not show significant differences between gastric cancer patients and control group. In contrast, when we stratified the population for gender, we found significant association between *BUB1B* rs1801376 genotypes and higher risk for developing gastric tumours (p = 0.029). Similarly, dominant model combining genotypes A/G and G/G showed comparable results (p = 0.010; p \[Yates correction\] = 0.017). Furthermore, tests for association showed analogous results and confirmed significantly higher frequency of G allele in female population of patients with gastric cancer (0.41 *vs*. 0.28 in control group). We also observed allele frequency difference in male patient population for *BUB1B* rs1031963. The dominant model, combining genotypes TT+CT versus CC, showed that patients with C/C homozygous allele had significantly higher risk for developing gastric cancer.

Distribution and genotype frequencies of SNPs in *TKK* and *BUB1B* between European and Slovenian populations {#j_raon-2015-0047_s_011}
-------------------------------------------------------------------------------------------------------------

Comparisons of the SNPs' genotype frequencies between our test groups and European populations are presented in [Figure 3](#j_raon-2015-0047_fig_003){ref-type="fig"}. Genotype frequencies of rs151658, rs1031963 and rs1801376 in our groups of populations showed significant differences from European population ([Table 6](#j_raon-2015-0047_tab_006){ref-type="table"}). The frequency of rs151658 C/C genotype was higher than expected in the Slovenian population of patients compared to total European population (p = 0.015). Similarly, we observed more rs1031963 C/C genotypes in the male population of Slovenian patients with gastric cancer (p = 0.042) compared with total European population and European population stratified for males. The rs1801376 A/G genotype was higher and A/A genotype was under-represented in female population of patients with gastric cancer compared to the total European population (p = 0.034) and female European population (p = 0.014).

###### 

Comparison of *TTK* rs151658, *BUB1B* rs1031963, and *BUB1B* rs1801376 genotypes between the European population and examined groups of Slovenian population

  Population               N     Genotype counts                        P
  ------------------------ ----- -------------------------------------- ---------------------------------------------------------------
  *TTK* rs151658                                                        
  EUR                      503   97 (C\|C) / 246 (C\|G) / 160 (G\|G)    χ^2^ = 8.391; P = 0.015 ^a^ χ^2^ = 11.143; P = 0.004 ^b^ NS c
  SI (total)^a^            283   80 (C\|C) / 124 (C\|G) / 79 (G\|G)     
  SI (cases)^b^            108   36 (C\|C) / 48 (C\|G) / 24 (G\|G)      
  SI (controls)^c^         175   44 (C\|C) / 76 (C\|G) / 55 (G\|G)      
  *BUB1B* rs1031963                                                     
  EUR                      503   125 (C\|C) / 259 (C\|T) / 119 (T\|T)   NS ^d^ NS ^e^ χ^2^ = 5.715; P = 0.057 ^f^
  EUR - male               240   56 (C\|C) / 124 (C\|T) / 60 (T\|T)     \_ c \_ d χ^2^ = 6.348; P = 0.042 ^f^
  SI (total)^d^            280   80 (C\|C) / 143 (C\|T) / 57 (T\|T)     
  SI (cases - female)^e^   36    6 (C\|C) / 23 (C\|T) / 7 (T\|T)        
  SI (cases - male)^f^     65    25 (C\|C) / 29 (C\|T) / 11 (T\|T)      
  ***BUB1B* rs1801376**                                                 
  EUR                      503   240 (A\|A) / 217 (A\|G) / 46 (G\|G)    NS ^g^ F = 6.569; P = 0.034 ^h^ NS ^1^
  EUR - female             263   135 (A\|A) / 109 (A\|G) / 19 (G\|G)    \_ g F = 8.277; P = 0.014 ^h^ \_ i
  SI (total)^g^            279   136 (A\|A) / 118 (A\|G) / 25 (G\|G)    
  SI (cases - female)^h^   40    11 (A\|A) / 25 (A\|G) / 4 (G\|G)       
  SI (cases - male)^i^     68    36 (A\|A) / 24 (A\|G) / 8 (G\|G)       

EUR = European population; F = Fisher statistics; SI (cases) = gastric cancer patients; SI (controls) = control population; SI (total) = combined populations of patients and controls; χ^2^ = chi-square statistics; superscript letters indicate comparisons between European population and Slovenian populations

TTK abundance is altered in tumour tissues of gastric cancer patients {#j_raon-2015-0047_s_012}
---------------------------------------------------------------------

Immunobloting data on individual samples ([Figure 1A](#j_raon-2015-0047_fig_001){ref-type="fig"}) demonstrated statistical significance for the increased abundance of TTK (p = 0.03) in the tumour tissues. No statistically significant correlation of TTK abundance with clinical his topathological parameters or rs151658 genotypes was observed. However, some trends were observed ([Figures 1B and C](#j_raon-2015-0047_fig_001){ref-type="fig"}) for lymph node involvement (pN) and antral tumour location: TTK abundance was higher in normal tissues compared to tumour tissues when no regional nodes were invaded with tumour cells (pN = 0) and when the tumours were located at the bottom of the stomach (antrum).

![Immunoblotting of TTK. (A) Densitometry quantification analysis for the relative band densities from the protein abundance immunoblotting for the indicated protein in the non-tumour (N) and tumour (T) gastric tissues. The p value given (Wilcoxon signed-rank test) indicates the significance of the difference between the non-tumour (N) and tumour (T) gastric tissue samples. (B, C) Densitometry quantification analysis for the relative band densities from the protein abundance immunoblotting for TTK in the non-tumour (N) and tumour (T) gastric tissues samples according to lymph node involvement (pN) and location of the tumours.](j_raon-2015-0047_fig_001){#j_raon-2015-0047_fig_001}

Prediction of binding motifs showed that polymorphic sites in *TTK* and *BUB1B* bind different transcription factors {#j_raon-2015-0047_s_013}
--------------------------------------------------------------------------------------------------------------------

To determine if different intronic polymorphisms could affect binding of transcription factors, we performed *in silico* analysis of conserved human motifs using polymorphic sequences as templates ([Figure 2](#j_raon-2015-0047_fig_002){ref-type="fig"}). We identified distinct recognition sites for different proteins for both *TTK* rs151658 and *BUB1B* rs1031963. TFII-I, c-Myb, NFI/CTF, and HNF-4 alpha binding motifs were recognized if rs151658 polymorphic site contained C allele. In contrast, if G allele was present, GR, TFII-I, NCFI/CTF, and HNF-4 alpha were identified. Comparison of rs1031963 alleles showed that if allele T was present, several binding motifs were predicted, whereas in the case of allele C, there were no recognizable binding patterns.

![Predicted binding sites for transcription factors for polymorphic alleles rs1031963 and rs151658.](j_raon-2015-0047_fig_002){#j_raon-2015-0047_fig_002}

![Distribution of genotype frequencies of polymorphisms rs151658, rs1031963, and rs1801376 between European populations and Slovenian population.\
CEU = Utah Residents (CEPH) with Northern and Western European Ancestry; EUR = European population; FIN = Finnish in Finland; GBR = British in England and Scotland; IBS = Iberian Population in Spain; SI (cases) = gastric cancer patients; SI (controls) = control population; SI (total) = combined populations of patients with gastric cancer and healthy controls; TSI = Tuscany in Italy](j_raon-2015-0047_fig_003){#j_raon-2015-0047_fig_003}

Discussion {#j_raon-2015-0047_s_014}
==========

In this study, we investigated the effects of selected polymorphisms in mitotic kinases *TTK* and *BUB1B*and risk of developing gastric cancer in Slovenian population. We also determined the associations between tested polymorphisms and clinic-pathological features of patients. The results provide evidence that *TTK* rs151658, *BUB1B* rs1031963, and rs1801376 could potentially serve as prognostic biomarkers for determining tumour differentiation and invasion. Furthermore, rs1801376 G allele could be used as one of determinants for gastric cancer screening in female population and CC genotype in rs1031963 could be used for selection of male population at higher risk for developing gastric cancer.

*TTK* gene harbours more than 600 different one-nucleotide polymorphisms (data obtained from GeneCards, <http://www.genecards.org/>). We investigated intronic polymorphism, because this gene has many alternative transcripts, and intronic one-nucleotide variants could have an effect on splicing and/or ubiquitination.[@j_raon-2015-0047_ref_35],[@j_raon-2015-0047_ref_36] SNP rs151658 lies between exons 12 and 13. In its vicinity there are binding sites for TFII-I, c-Myb, NFI/ CTF, and HNF-4 alpha transcription factors, if C allele is present and binding sites for GR, TFII-I, NFI/CTF, and HNF-4 alpha, if G allele is present (PROMO, ALGGEN server) ([Figure 2](#j_raon-2015-0047_fig_002){ref-type="fig"}).[@j_raon-2015-0047_ref_32],[@j_raon-2015-0047_ref_33] This indicated that different polymorphic alleles bind different proteins, which could in turn affect splicing or gene expression. Studies, performed on breast cancer patients, confirmed the significant association of this polymorphism with cancer risk[@j_raon-2015-0047_ref_15]; however, we did not find any studies regarding the effect of rs151658 on gastric cancer risk. In our study, we identified the association of G/G geno-type with intestinal type of gastric cancer, while C/G genotype was significantly increased in cases with diffuse type of gastric cancer. Interestingly, comparison of genotype distribution for rs151658 between Slovenian patients with gastric cancer and European population showed that C/C genotype was over-represented in patients with gastric cancer. The significance of this finding is not clear and further analyses are needed on larger cohorts of patients in order to determine its usefulness in clinical setting.

To assess if the above mentioned genotypes perhaps had an effect on TTK protein levels, immunoblotting was performed. While the results regarding the effect of genotypes on protein abundance remain inconclusive, it should be noted that polymorphisms usually exert low-penetrance effects, which could more profoundly affect the pathogenesis of gastric cancer in early stages; however, when the disease progresses, the mutation load and aberrant expression of other genes mask their effects. We did, however, confirm higher abundance of TTK in tumour tissues, which is in accordance with several other studies and points out the deregulation of cell cycle homeostasis, higher proliferative trend of tumour cells and weakened spindle assembly checkpoint leading to increased genome instability and aneuploidy.[@j_raon-2015-0047_ref_37],[@j_raon-2015-0047_ref_38] Furthermore, this study showed a trend of increased TTK abundance associated with the spread of cancer cells to regional lymph nodes indicating a possible link between TTK levels and metastatic potential of malignant gastric cells.

Homozygous mutations of critical spindle-assembly *BUB1B* are extremely rare and associated with the diseases such as mosaic variegated aneuploidy syndrome 1 (biallelic mutations) and premature chromatid separation trait, which are both characterized by aneuploidy and chromosomal instability.[@j_raon-2015-0047_ref_39] *BUB1B* overexpression has been found in gastric cancers, although the results are often conflicting. In one study, the overexpression of *BUB1B* was associated with tumour proliferation[@j_raon-2015-0047_ref_40], however, Enjoji *et al*. observed that patients with higher expression of *BUB1B* had improved relapsefree survival.[@j_raon-2015-0047_ref_41] Furthermore, Ando *et al*. found that high expression of *BUB1B* correlated with invasion, lymph node metastasis, liver metastasis, and poor prognosis.[@j_raon-2015-0047_ref_14] Bohers *et al*. confirmed that the function of *BUB1B* is dosage-dependent by gradual reduction of *BUB1B* expression by shRNA in cell lines.[@j_raon-2015-0047_ref_42] In their experiment, residual levels of BUB1B protein below 50% of the normal level indicated premature chromatid separation and aneuploidy. These conflicting effects of BUB1B could be mediated by different polymorphisms, present in the nucleotide sequence of the gene. *BUB1B*rs1031963 polymorphism is in 5'-promoter region, which harbours binding sites for C/EBPbeta, GR, HNF-4alpha, LEF-1, SRY, TCF-4E, and TCF4 if T allele is present (PROMO, ALGGEN server).[@j_raon-2015-0047_ref_32],[@j_raon-2015-0047_ref_33]Interestingly, if C allele is present, the DNA sequence harbours no transcription factor motifs. In our study the T/T genotype was associated with well differentiated tumours in total population, whereas in female population, when analysed separately, it was associated with moderately differentiated tumours. Well differentiated adenocarcinomas tend to have a better prognosis than infiltrative poorly differentiated adenocarcinomas. Furthermore, T/T+C/T genotypes were nominally associated with reduced risk of gastric cancer in male population, whereas C/C genotype was more common in male patient population. Comparisons with European population showed similar results. *BUB1B* rs1801376 A/A genotype was significantly higher in female patients with diffuse gastric cancer. A/A genotype was also increased in samples, which were characterized by invasion of tumour cells into subserosa in male population, and was associated with tumours, growing throughout whole stomach tissue. The consequence of this functional polymorphism is amino acid substitution Q349R in conserved region KEN, which is the binding site for CDC20.[@j_raon-2015-0047_ref_43] CDC20 is co-activator of anaphase promoting complex APC/C.[@j_raon-2015-0047_ref_24] Impaired function of KEN region in *BUB1B* could thus affect the regulation of anaphase delay, which ensures genome stability by providing time for correct spindle assembly, chromosome alignment and segregation. In addition, A/G genotype showed significant association with gastric cancer risk in female population of gastric cancer patients compared to Slovenian control group and European population.

In conclusion, our study provides evidence that polymorphisms in mitotic kinases *TTK* rs151658, *BUB1B* rs1031963 and rs1801376 could have an effect on gastric tumorigenesis and risk of adenocarcinoma development. In addition, we observed differences in genotype distributions between certain clinic-pathological features in patient populations, which could be used as the diagnostic aid in clinical setting; however, a large scale evaluation of these polymorphisms and functional analyses of their effect on protein products are needed to confirm their role in gastric carcinogenesis.
